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Abstract
Background: The current antibody detection tests for the diagnosis of gambiense human African trypanosomiasis (HAT) are
based on native variant surface glycoproteins (VSGs) of Trypanosoma brucei (T.b.) gambiense. These native VSGs are difficult
to produce, and contain non-specific epitopes that may cause cross-reactions. We aimed to identify mimotopic peptides for
epitopes of T.b. gambiense VSGs that, when produced synthetically, can replace the native proteins in antibody detection
tests.
Methodology/Principal Findings: PhD.-12 and PhD.-C7C phage display peptide libraries were screened with mouse
monoclonal antibodies against the predominant VSGs LiTat 1.3 and LiTat 1.5 of T.b. gambiense. Thirty seven different
peptide sequences corresponding to a linear LiTat 1.5 VSG epitope and 17 sequences corresponding to a discontinuous
LiTat 1.3 VSG epitope were identified. Seventeen of 22 synthetic peptides inhibited the binding of their homologous
monoclonal to VSG LiTat 1.5 or LiTat 1.3. Binding of these monoclonal antibodies to respectively six and three synthetic
mimotopic peptides of LiTat 1.5 and LiTat 1.3 was significantly inhibited by HAT sera (p,0.05).
Conclusions/Significance: We successfully identified peptides that mimic epitopes on the native trypanosomal VSGs LiTat
1.5 and LiTat 1.3. These mimotopes might have potential for the diagnosis of human African trypanosomiasis but require
further evaluation and testing with a large panel of HAT positive and negative sera.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is
caused by the protozoan flagellar parasites Trypanosoma brucei (T.b.)
gambiense and T.b. rhodesiense. The disease is transmitted by tsetse
flies (Glossina spp.) and therefore only occurs in sub-Saharan
Africa. The number of cases is currently estimated between 50 000
and 70 000 [1].
Control of T.b. gambiense HAT is largely based on accurate
diagnosis and treatment of the human reservoir [2]. Detection
of parasites in blood, lymph node aspirate or cerebrospinal fluid
is laborious and insensitive, and therefore only applied on
suspected HAT patients. In the absence of reliable antigen
detection tests, the screening of the population at risk relies on
the detection of antibodies against variant surface glycoproteins
(VSGs) [2]. These immunogenic VSGs form a dense monolayer
of homodimers that completely covers the surface of blood-
stream trypanosomes and determines the variable antigen type
(VAT) of the individual trypanosome [3]. The parasite genome
contains hundreds of VSG genes and trypanosomes switch from
the expression of one VSG gene to another. This antigenic
variation enables the parasite population to survive the host’s
immune response. Each VSG monomer contains 400–500
amino acids and consists of two domains, a variable N-terminal
domain with little primary sequence homology and a relatively
conserved C-terminal domain. A glycosylphosphatidylinositol
anchor links the C-terminal domain to the cell membrane. All
N-terminal domains fold in a similar three-dimensional
structure, exposing only a limited subset of, probably discon-
tinuous, epitopes [4–7].
The current T.b. gambiense antibody detection tests are based on
native VSGs from the VATs LiTat 1.3, LiTat 1.5 and LiTat 1.6 of
T.b. gambiense [8]. These predominant VATs appear early during
infection, and induce a strong and specific immune response in
most patients [3]. The card agglutination test for trypanosomiasis
(CATT) [9], most widely used for mass screening of populations at
risk, consists of whole lyophilised trypanosomes of VAT LiTat 1.3
and has a sensitivity on whole blood of 87–98% and a specificity
around 95% [2]. Although VSG LiTat 1.3 is not expressed in all
endemic HAT foci [10,11], the low sensitivity of CATT in those
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is the case in the LATEX/T.b. gambiense and the ELISA/T.b.
gambiense where the combination of VSG LiTat 1.3, 1.5 and 1.6 is
used as antigen [12,13].
The use of native VSGs as diagnostic antigens has several
disadvantages. Firstly, non-specific epitopes on the native antigens
may cause cross-reactions and decrease test specificity. Secondly,
VSG production relies on culture of infective T.b. gambiense
parasites in laboratory rodents and poses a risk of infection to the
staff [14]. These disadvantages might be avoided if native antigens
are replaced by synthetic peptides. The production of synthetic
peptides is standardised, does not require laboratory animals and
is without risk of infection [15].
Peptide phage display is a selection technique based on DNA
recombination, resulting in the expression of foreign peptide-
variants on the outer surface of phage virions. After an in vitro
selection process based on binding affinity, called panning, the
selected peptides are characterised by DNA sequencing. Phage
display is a powerful tool to identify mimotopes, small peptides
that mimic linear, discontinuous and/or non-protein epitopes [16–
18]. Mimotopes with diagnostic potential have already been
identified, e.g. for detection of specific antibodies for Lyme disease
[19], hepatitis C [15,20], typhoid fever [21], tuberculosis [22] and
leishmaniasis [23]. Some mimotopes have been patented to
become incorporated in commercially available tests, e.g. for
neurocysticercosis [24].
In this study, we aimed to identify mimotopes for epitopes of T.
b. gambiense VSG LiTat 1.3 and LiTat 1.5 that may replace the
native proteins in antibody detection tests for sleeping sickness.
Materials and Methods
Ethics statement
Samples from HAT patients and endemic controls were
collected within an observational study [13]. All individuals gave
their written informed consent before providing serum. Permission
for this study was obtained from the national ethical committee of
DRC and from the ITM ethical committee, reference number 03
07 1 413.
Anti-VSG monoclonal antibodies
Monoclonal antibodies (mAbs) H12H3 (IgG3, anti-VSG LiTat
1.5), H13F7 (IgG3, anti-VSG LiTat 1.3) and H18C11 (IgG1, anti-
VSG LiTat 1.3) were generated by intraperitoneal infection of
Balb/c mice with 10
6 T.b. gambiense LiTat 1.3 and 10
6 LiTat 1.5
cloned parasites. After 2 weeks, splenocytes were isolated and
fused with NS0 myeloma cells [25]. Anti-VSG antibody producing
hybridomas were identified by enzyme linked immunosorbent
assay (ELISA) and further propagated. The antibodies were
purified from culture supernatant on protein A agarose. The SBA
Clonotyping
TM system/HRP kit (Southern Biotech) was used for
mAb isotyping.
Coating of magnetic particles with anti-VSG mAbs
Anti-VSG mAbs were coated onto anti-mouse IgG functiona-
lised magnetic particles (MP) (1% w/v, 0.35 mm, Estapor/Merck)
at a concentration of 30 mg/g MP and stored in phosphate
buffered saline (PBS, 0.01 mol/L phosphate, 0.14 mol/L NaCl,
pH 7.4) containing 0.1% (w/v) bovine serum albumin (PBS-BSA).
The coated MP were washed eight times with PBS containing
0.25% w/v gelatine and 0.1% v/v Tween-20 (PBSGT) and
resuspended 0.25% w/v gelatine in PBS (PBSG). Successful
coating of the MP was confirmed by agglutination of VSG coated
latex beads (LATEX/T.b. gambiense) [12]. Anti-VSG mAb-free
MPs were prepared by omitting the coating step.
Selection of mimotopes by panning of phage-displayed
peptides
Pannings were performed with the Ph.D.-12 (12-mer) and the
Ph.D.-C7C (cyclic 7-mer) phage display libraries (New England
Biolabs, NEB) through two rounds consisting of 1) a positive
selection with anti-VSG mAbs coated on MP, 2) a negative
selection with anti-VSG mAb-free MP and 3) phage amplification.
After these two rounds a third positive selection was performed.
Positive selection
For positive selection, 10 mL of the phage display library (for the
1
st positive selection) or 100 mL of amplified phage (for the 2
nd and
3
rd positive selection) were mixed overnight (ON) at 4uC with
1 mg mAb coated-MP in PBSG in a total volume of 1 mL. MP
were washed ten times with PBSGT and bound phages were
eluted by antigen competition (A) followed by acid elution (P). For
the antigen competition, the MP were incubated for 1 h with
700 mL PBS containing 0.23 mg of corresponding VSG. After
collection of the supernatant containing the eluted phages, MP
were washed three times with PBSGT. The remaining bound
phages were eluted with 600 mL of 0.2 mol/L glycine-HCl
containing 1 mg/mL BSA (pH 2.2) and neutralised with 90 mL
of Tris-HCl (1 mol/L, pH 9.1).
Negative selection
The phages eluted from the positive selection were mixed
overnight at 4uC with 1 mg of anti-VSG mAb-free MP in a total
volume of 1 mL of PBSG. The phages in the supernatant were
amplified.
Amplification and purification of phages
Phages were amplified in Escherichia (E.) coli (strain ER2738,
NEB) in lysogeny broth (LB), supplemented with tetracycline
(20 mg/mL) [26]. After 4.5 h shaking at 37uC, bacteria were
pelleted by centrifugation (30 min, 1811 g). The phages in the
supernatant were precipitated overnight at 4uC with 25% w/v
polyethylene glycol-6000 in 2.5 mol/L NaCl (PEG-NaCl). Phages
Author Summary
The control of human African trypanosomiasis or sleeping
sickness, a deadly disease in sub-Saharan Africa, mainly
depends on a correct diagnosis and treatment. The aim of
our study was to identify mimotopic peptides (mimotopes)
that may replace the native proteins in antibody detection
tests for sleeping sickness and hereby improve the
diagnostic sensitivity and specificity. We selected peptide
expressing phages from the PhD.-12 and PhD.-C7C phage
display libraries with mouse monoclonal antibodies
specific to variant surface glycoprotein (VSG) LiTat 1.3 or
LiTat 1.5 of Trypanosoma brucei gambiense. The peptide
coding genes of the selected phages were sequenced and
the corresponding peptides were synthesised. Several of
the synthetic peptides were confirmed as mimotopes for
VSG LiTat 1.3 or LiTat 1.5 since they were able to inhibit the
binding of their homologous monoclonal to the corre-
sponding VSG. These peptides were biotinylated and their
diagnostic potential was assessed with human sera. We
successfully demonstrated that human sleeping sickness
sera recognise some of the mimotopes of VSG LiTat 1.3
and LiTat 1.5, indicating the diagnostic potential of such
peptides.
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resuspended in 1 mL of PBS. Residual bacteria were pelleted by
centrifugation (5 min, 15700 g) and phage precipitation with
PEG-NaCl was repeated for 2 to 4 hours at 4uC. After
centrifugation (20 min, 15700 g, 4uC) the phage pellet was
resuspended in 200 mL of PBS with 0.02% w/v NaN3.
After a third positive selection, phages selected through three
antigen competition elutions (AAA) and three acid elutions (PPP)
were titered as described below.
Titering of phages
Phages were titered to obtain well separated, single plaques for
analysis. Phages were diluted 10
3 to 10
7 in PBS, mixed with an E.
coli culture and plated on agar plates containing 1 mL/L IPTG/
X-gal (1.25 g isopropyl b-D-thiogalactoside, 1 g 5-bromo-4-
chloro-3-indolyl-b-D-galactoside, 25 mL dimethylformamide). Af-
ter the 3
rd positive selection 94 blue clones were picked and each
clone was inoculated in 200 mL of LB in a sterile culture plate (BD
Falcon
TM Clear 96-well Microtest
TM Plate). This plate was shaken
overnight at 30uC, where after the bacteria were pelleted by 5 min
centrifugation at 1312 g. The supernatant was tested in a
sandwich ELISA with the homologous mAb. Based on these
results, twenty phages per elution method were amplified, tested in
a sandwich ELISA with all three mAbs and amplified for DNA
extraction.
Single-stranded DNA extraction and sequencing
Purification of phage DNA was performed according to the
NEB manual [26]. Sequence determination was performed at the
VIB Genetic Service Facility of the University of Antwerp with the
296 gIII sequencing primer, 59-
H0CCC TCA TAG TTA GCG
TAA CG-39 (NEB). The obtained sequence chromatograms were
read with Chromas 2.33 (Technelysium Pty Ltd). Sequence
alignment was performed manually and with RELIC software
[27]. We searched for discontinuous epitopes with the 3D-
Epitope-Explorer (3DEX) [28] and visualised the sequences on the
protein model with PyMOL pdb viewer (PyMOL Molecular
Graphics System, Schro ¨dinger, LLC).
Sandwich ELISA with phage particles
ELISA plates (Nunc MaxiSorp
TM) were coated with 5 mg/mL
anti-VSG mAb in PBS (100 mL/well) and incubated ON at 4uC.
Plates were saturated for 1 h at rT with 350 ml PBS-Blotto
(0.01 mol/L phosphate, 0.2 mol/L NaCl, 1% w/v skimmed milk
powder, 0.05% w/v NaN3 ) and washed three times with 0.05%
v/v Tween-20 in PBS (PBST) (ELx50, Bio-Tek ELISA washer).
Wells were incubated for 4 h at rT with 100 mL of phage dilution
in PBS-Blotto (1/3 for culture plate supernatant or 1/20 for PEG-
NaCl purified phage). After three washes, horse radish peroxidase
(HRP)-labelled anti-M13 pVIII mAb (GE Healthcare), diluted 1/
2000 in PBST was added to the wells for 1 h at rT (100 ml/well).
After another five washes, wells were incubated for 1 h at rT with
100 mL/well of 2.29-azino-bis-(3-ethylbenzthiazoline-6-sulfonic
acid) (ABTS) chromogen/substrate solution (50 mg tablet/
100 mL of ABTS buffer, Roche). The plate was shaken for
10 seconds and the optical density (OD) was read at 414 nm
(Labsystems Multiskan RC 351).
Peptide synthesis
Peptide selection for synthesis (Eurogentec, Belgium) was based
on strong, reproducible and specific reaction of phage clones with
their homologous anti-VSG mAb in ELISA, prediction of peptide
hydrophilicity and common motive groups in the sequences. The
12-mer linear peptides were synthesised at .70 or .85% purity.
The C-terminus was elongated with a GGGS-CONH2 tail to
mimic the GGGS-peptide spacer between the random peptide
sequence and the phage protein pIII and to block the negative
charge of the carboxyl terminus. The cyclic 7-mer sequences were
synthesised at .90% purity. The 7-mer peptides were flanked by
two cysteines, and the C-terminus was elongated with GGGS-
CONH2. The biotinylated peptides were synthesised at .85%
purity, with an additional lysine-biotin added to the C-terminus.
All synthetic peptides were reconstituted in sterile deionised H2O
to a concentration of 2 mg/mL.
Inhibition ELISA with synthetic peptides and anti-VSG
mAbs
The capacity of the synthetic peptides to mimic the natural
VSG epitopes was assessed in an inhibition ELISA. Peptide
dilution series of 200, 67, 22, 7 and 0 mg/ml or 67, 22, 7, 2 and
0 mg/ml were prepared in PBS containing 1% BSA (PBS-BSA)
with mAb H12H3 at 1 mg/mL, and in PBS-Blotto with mAb
H13F7 at 11 mg/mL or mAb H18C11 at 0.04 mg/mL. The same
dilution series were prepared in PBS-BSA or PBS-Blotto but
without mAb. These dilutions were rotated ON at 4uC. All
samples were tested in duplicate.
For mAb H12H3, ELISA plates were coated ON at 4uC with
100 mL/well of 2 mg/mL VSG LiTat 1.5 in PBS and antigen-free
wells served as an antigen negative control. The next day, ELISA
plates were blocked at rT for 1 h with PBS-BSA and washed three
times with PBST. The wells were incubated for 1 h at rT with
100 ml of the dilutions. Plates were washed three times and HRP-
labelled goat Fc-specific anti-mouse IgG conjugate (Jackson),
diluted 1/500 in PBST was added for 1 h (100 mL/well, rT). The
colour reaction was performed as previously described for the
sandwich ELISA. For the mAbs H13F7 and H18C11 the same
protocol was followed, using VSG LiTat 1.3, PBS-Blotto 1% and a
1/1000 dilution of the anti-mouse conjugate.
The remaining activity (% RA) was calculated: first, for each
peptide dilution, the average OD measured in the antigen-free
control wells was subtracted from the average OD in the
corresponding antigen containing wells, thus yielding ODa.
Second, the corrected ODc was obtained by subtracting the
ODa obtained in the mAb-free wells from the ODa in the
corresponding mAb containing wells. Finally, the % remaining
activity was calculated as 1006ODc/ODmax, where ODmax was
the ODc of wells receiving the peptide-free mAb dilution.
Indirect ELISA with biotinylated peptides and anti-VSG
mAbs
Nunc MaxiSorp
TM plates were coated with 100 mL/well of
10 mg/mL streptavidin (NEB) in carbonate buffer (CB, 0.1 mol/L,
pH 9.2). Plates were incubated ON at 4uC. After saturation with
PBS-BSA (for mAb H12H3) or PBS-Blotto (for mAb H13F7) and
three washes with PBST, wells were filled with 100 mLo f
biotinylated peptide in PBS at a concentration of 5 (only for
peptide 24, C57 and C59), 1, 0.6, 0.3 and 0 mg/ml. After 1 h at rT,
wells were washed three times and incubated for 1 h with 100 mL
mAb (mAb H12H3 at 1.07, 0.53, 0.27 mg/mL in PBS-BSA or mAb
H13F7 at 0.53 and 0.27 mg/mL in PBS-Blotto). After three washes,
HRP-labelled goat anti-mouse IgG (Fcc) conjugate was diluted 1/
1000 in PBST and added at 100 mL/well for 1 h. After five washes,
plates were incubated for 1 h with 100 mL/well of ABTS. The OD
was read at 414 nm and corrected by subtracting the OD obtained
inthepeptide-freewellsfrom the OD obtained inthecorresponding
peptide containing wells.
Peptide Mimotopes of Trypanosoma brucei gambiense
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sera
The capacity of the synthetic peptides to specifically bind
antibodies in serum from HAT patients was assessed in an
inhibition ELISA with nine sera from gambiense sleeping sickness
patients and ten sera from endemic controls. ELISA plates were
coated ON at 4uC with 100 mL/well of 10 mg/mL streptavidin in
CB. All samples were tested in duplicate. The following day the
plates were saturated with PBS-BSA (for mAb H12H3) or PBS-
Blotto (for mAb H13F7). The dilutions of the biotinylated peptides
were made in PBS (0.01 mol/L phosphate, 0.14 mol/L NaCl,
pH 6), ranging from 20 mg/mL to 0.3 mg/mL, depending on the
peptide. After three washes with PBST, the peptide dilutions were
added at 100 mL/well and left for 1 h at rT. Plates were tapped
dry, sealed and stored frozen at 280uC. Just before use, plates
were thawed and washed (36PBST). Wells were incubated with
100 mL of a 1/5 human serum dilution in PBS-BSA or PBS-
Blotto, depending on the mAb (1 h at rT). After three washes with
PBST, mAb H12H3 (in PBS-BSA) or mAb H13F7 (in PBS-Blotto)
was added at a concentration ranging from 1 to 0.25 mg/mL,
depending on the peptide (100 ml/well, 1 h, rT). Plates were
washed three times and a 1/1000 dilution in PBST of HRP
labelled goat anti-mouse IgG (Fcc) conjugate was added at
100 mL/well (1 h, rT). Plates were washed five times and
incubated for 1 h at rT with 100 mL/well of ABTS. The OD
was read at 414 nm and corrected by subtracting the average OD
obtained in the antigen-free wells from the average OD obtained
in the corresponding antigen containing wells, thus yielding ODc.
The percent remaining activity was calculated as 1006ODc/
ODmax. P-values were tested with the Wilcoxon rank test (positive
versus negative) and corrected for multiple comparisons with the
Bonferroni method.
Human serum samples
Based on the results in indirect ELISA with VSG LiTat 1.5 and
LiTat 1.3 (data not shown) we selected nine HAT positive
(OD.1.5) and 10 endemic negative (OD,0.2) human serum
samples originating from a study on detection of specific antibodies
in serum and saliva in the Democratic Republic of Congo (DRC)
[13].
Results
Peptide selection with anti-LiTat 1.5 mAb H12H3
Panning of the Ph.D.-12 library yielded phage clones for which
median ODs in the sandwich ELISA with the homologous mAb
were 1.352 (interquartile range, IQR, 1.119–1.608) for the AAA
elution and 2.759 (IQR 2.384–2.943) for the PPP elution. Twenty
phage clones eluted with AAA and OD.1 and twenty phage
clones eluted with PPP and OD.2, were selected for amplifica-
tion, cross reactivity testing and sequencing. All forty amplified
phage clones reacted specifically with mAb H12H3 (median OD
1.055 with H12H3 versus 0.100 with the heterologous mAb
H13F7 and H18C11), therefore excluding that the selected phage
clones bound to the conserved Fc part of the mAbs. Phages
obtained with the AAA elution expressed six different amino acid
(AA) sequences (fig. 1). One sequence could not be read. Phages
obtained with the PPP elution expressed nine different sequences.
Panning of the Ph.D.-C7C library yielded phage clones for
which median ODs in the sandwich ELISA with the homologous
mAb were 0.713 (IQR 0.485–2.338) for the AAA elution and
3.218 (IQR 3.138–3.324) for the PPP elution. Twenty phage
clones eluted with AAA and OD.2 and twenty phage clones
eluted with PPP and OD.3, were selected for amplification, cross
reactivity testing and sequencing. All amplified phage clones
reacted specifically with mAb H12H3 (median OD 3.106 with
H12H3 versus 0.138 with the heterologous mAbs H13F7 and
H18C11). Five phage clones corresponding to three sequences did
not amplify well (OD with mAb H12H3,0.4) and were not
withheld for further experiments. With each elution method,
phages expressing twelve different amino acid sequences were
obtained (fig. 1). Two of these sequences were found in both the
AAA and the PPP elution, bringing the total of different C7C-
sequences to twenty-two.
Amongst the thirty-seven different sequences obtained through
panning with mAb H12H3, four groups of common motives could
be distinguished (fig. 1). Amino acids with similar structure and
characteristics were considered homologous, such as arginine (R)
and lysine (K); serine (S) and threonine (T); glutamine (Q) and
asparagine (N); alanine (A), valine (V), leucine (L) and isoleucine
(I); phenylalanine (F), tyrosine (Y) and tryptophan (W); and
aspartic acid (D) and glutamic acid (E). Group 1 with common
motive SAP(W/Y)(V/A,S or N)(L/A or Y/F/W)(R/K)DH(L/A
or Y/F)(P or S/T)L/AxG contained all the Ph.D.-12 sequences,
and part of the Ph.D.-C7C sequences. Group 2, 3 and 4 consisted
of Ph.D.-C7C sequences only and had as a common motive
AxxxT(S/T or A)(P or L) (N/Q)QWL, AxPVYExHWxxxG, and
AxQxPHxxxxG respectively. The sequence CTDFEGMLC did
not have more than two AA in common with one of the other
sequences and is displayed separately.
Homology between peptides and the protein sequence of VSG
LiTat 1.5 [GenBank HQ662603] was found within AA 268 to 281
of the protein sequence (maximum 42.86% or 6/14 identical AA,
fig. 1), in the variable N-terminal domain of VSG LiTat 1.5.
Out of the thirty-seven obtained sequences, ten peptides were
synthesised. All ten synthetic peptides strongly inhibited the
binding of mAb H12H3 to native VSG LiTat 1.5 in a dose
dependent manner (,25% remaining activity at a peptide
concentration of 67 mg/ml) (fig. 1) and were resynthesised with a
C-terminal lysine-biotin. Peptides selected with mAb H13F7 and
H18C11 (see below) did not inhibit binding of H12H3 to VSG
LiTat 1.5, (data not shown). All biotinylated peptides were
recognised by mAb H12H3 in an indirect ELISA. A peptide
concentration of .10 mg/mL was necessary to obtain an OD.0.5
with peptides C57 and C59 while 5 mg/mL for peptide 24 and
concentrations ranging from 0.3 to 0.6 mg/mL for the other seven
peptides, were sufficient to obtain an OD.1 (data not shown).
Peptide selection with anti-LiTat 1.3 mAb H13F7
Panning of the Ph.D.-12 library yielded phage clones for which
median ODs in the sandwich ELISA with the homologous mAb
were 3.219 (IQR 3.000–3.350) for the AAA elution and 0.148
(IQR 0.123–2.999) for the PPP elution. Per elution method,
twenty phage clones with OD.2 were selected. All forty amplified
clones reacted specifically with mAb H13F7 (median OD 3.022
with H13F7 versus 0.113 with the heterologous mAbs H12H3 and
H18C11); this excludes that the selected phage clones bound to the
conserved Fc part of the mAbs. Phages obtained with the AAA
elution, expressed seven different amino acid sequences. Phages
obtained with the PPP elution, expressed three different sequences.
One sequence was found in both the AAA and the PPP elution,
thus bringing the total of different sequences to nine (fig. 2).
Panning of the Ph.D.-C7C library yielded phage clones for
which median ODs in the sandwich ELISA with the homologous
mAb were 1.481 (IQR 0.739–1.869) with the AAA eluted phage
clones and 0.107 (IQR 0.087–0.122) with the PPP eluted phage
clones. None of the PPP eluted clones were withheld. Twenty
phage clones of the AAA elution with OD.1 were amplified. All
Peptide Mimotopes of Trypanosoma brucei gambiense
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H13F7 versus 0.106 with the heterologous mAbs H12H3 and
H18C11). Seven different amino acid sequences were expressed
(fig. 2).
Amongst the sixteen different sequences obtained with mAb
H13F7, three groups of common motives could be distinguished
(fig. 2). Group 1 with common motive PPxWINPFPxF
contained only 12-mer sequences. Group 2 contained some of
the 12-mer and all of the 7-mer sequences and had as common
motive PW(W or L)PLQ(W/Y)(I/V/L)F or, with ‘‘WPL’’ in
reverse order, Ax(I/V)L(P or S )WLH(I/V). Peptide 59 and
p e p t i d eC 6 3s h a r eac o m m o nm o t i ve, but in reverse order (F/
W)LPL. Group 3 consisted of two sequences with common
motive SPxMLH. Alignment of these sequences with the protein
sequence of VSG LiTat 1.3 [GenBank AJ304413], only gave
results for group 2 and one sequence of group 3. These had
maximum 28.57% identical AA (4/14) within respectively AA
stretch 196 to 210 and AA stretch 338 to 351 of VSG LiTat 1.3
(fig. 2). The motive W(AA 291)P(AA 290)L(AA 292)L(AA
234)T(AA 230) of peptide 64 could be mapped onto the three-
dimensional VSG LiTat 1.3 protein structure, in the N-terminal
domain (results not shown).
Out of the sixteen sequences selected with mAb H13F7, twelve
peptides were synthesised. Six synthetic peptides strongly inhibited
the binding of the mAb to the native VSG LiTat 1.3 (,50%
remaining activity at a peptide concentration of 67 mg/ml), and
one peptide was a weaker inhibitor (76% remaining activity) (fig. 2).
These seven peptides were resynthesised with a C-terminal lysine-
biotin and their reactivity with mAb H13F7 was assessed by
indirect ELISA. All biotinylated peptides had an OD.1 with mAb
H13F7 at a concentration of 0.6 to 0.3 mg/mL peptide (data not
shown).
Figure 1. Amino acid sequences of peptides obtained by phage display with anti- VSG LiTat 1.5 mAb H12H3. The first sequence
displayed is amino acid 265 to 288 of the protein sequence of VSG LiTat 1.5. Homologous amino acids are indicated in grey and amino acids that are
identical to those of the VSG protein sequence are in bold and grey. All peptide sequences include the GGGS-spacer (connecting phage protein pIII
and the random peptide in the original library) at the C-terminal. When expressed on the phage, the first cysteine of the C7C-peptides is preceded by
alanine. AAA: eluted via antigen competition. PPP: eluted via acidification. Freq: number of times this sequence was found amongst seventy-nine
selected phage clones. Name: name of the synthesised peptide.*: peptide selected for biotinylation. NW: not withheld. % identity: percentage identity
of the peptide sequence with a stretch of 14 AA (AA 268 to 281) within the protein sequence of VSG LiTat 1.5. % RA mAb-VSG: percentage remaining
of the mAb binding to its corresponding native VSG after inhibition by the synthetic peptide at 67 mg/ml.
doi:10.1371/journal.pntd.0001189.g001
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Panning of the Ph.D.-12 library yielded phage clones for which
median ODs in the sandwich ELISA with the homologous mAb
were 0.124 (IQR 0.109–0.185) for the AAA elution and 0.130
(IQR 0.108–0.148) for the PPP elution. None of the clones from
the Ph.D-C7C-library gave a sufficiently high OD to be amplified.
Twenty AAA eluted clones of the Ph.D.-12-library with OD.0.5
were amplified. All twenty clones reacted specifically with mAb
H18C11 (median OD 3.271 with H18C11 versus 0.106 with the
heterologous mAbs H12H3 and H13F7). Only one amino acid
sequence was expressed: SHSTPYYWKGYI. We could not
identify any homology between this peptide and the protein
sequence of VSG LiTat 1.3. The corresponding synthetic peptide
did not react with mAb H18C11 in indirect ELISA (data not
shown) and did not inhibit the binding of mAb H18C11 to native
VSG LiTat 1.3 and was therefore not withheld for further
experiments.
Assessment of the diagnostic potential of the
biotinylated peptides for HAT by inhibition ELISA with
human sera
The diagnostic potential of the biotinylated peptides was
assessed in an inhibition ELISA with human sera from nine
gambiense HAT patients and ten negative controls. Compared to
the HAT negative sera, the HAT positive sera significantly
inhibited binding of mAb H12H3 to peptide 23, C59 and C60
(p,0.05) and 21, 22, and 28 (p,0.01) (fig. 3). Five of these peptides
belong to common motive group 1, peptide C60 belongs to group
4 (fig. 1). The HAT positive sera also significantly inhibited
binding of mAb H13F7 to peptide 25 (p,0.05) and peptides 60
and 61 (p,0.01) (fig. 3). All three peptides belong to common
motive group 1 (fig. 2).
Discussion
By means of phage display technology we successfully identified
peptides that mimic epitopes on the native trypanosomal variant
surface glycoproteins LiTat 1.5 and LiTat 1.3 of T.b. gambiense.
These mimotopic peptides were recognised by the monoclonal
anti-VSG antibodies H12H3 and H13F7 that were used for
panning, and might have potential for the diagnosis of human
African trypanosomiasis.
Our results indicate that a linear region in the protein sequence
of VSG LiTat 1.5 was identified. This region is localised in the N-
terminal domain of the VSG near the surface of the trypanosome
and is therefore a candidate for further testing as a synthetic, linear
peptide. Antibodies specific to linear, continuous epitopes on
protein antigens typically contact three to four critical amino acids
over a six residue segment [16]. The peptide sequences selected
with mAb H12H3 had up to six amino acids (% identity 42.86) in
common with the variable N-terminal domain (AA 268 to 281) of
VSG LiTat 1.5. Glycine from the GGGS-spacer, inserted between
the peptide sequence and the pIII phage protein, was part of this
common motive. It is possible to define the exact residues in the
peptide sequences that are essential for binding with the antibody
by alanine scanning mutagenesis and recreate the epitope of each
monoclonal. A recent example has been the identification of a
linear epitope on the VP1 protein of foot-and mouth disease virus
by Yang et al. [29] by screening a 12-mer phage display library
with a mAb.
Contrary to VSG LiTat 1.5, we suspect the epitope of VSG
LiTat 1.3 to be discontinuous. Alignment of the peptide sequences
with the protein sequence of VSG LiTat 1.3 located the common
motives in different parts of the protein sequence with a maximum
% identity of only 28.57. Also, when the VSG was (partly)
denatured, the OD in ELISA with this mAb dropped. Many
Figure 2. Amino acid sequences of peptides obtained by phage display with anti-VSG LiTat 1.3 mAb H13F7. The amino acid stretches
196 to210 and 338 to 351 of the VSG LiTat 1.3 protein are displayed in group 2 and 3 respectively. Homologous amino acids are indicated in grey and
amino acids that are identical to those of the VSG protein sequence are in bold and grey. All peptide sequences include the GGGS-spacer (connecting
phage protein pIII and the random peptide in the original library) at the C-terminal. When expressed on the phage, the first cysteine of the C7C-
peptides is preceded by alanine. AAA: eluted via antigen competition. PPP: eluted via acidification. Freq: number of times this sequence was found
amongst fifty-nine selected phage clones. Name: name of the synthesised peptide.*: peptide selected for biotinylation. % identity: percentage
identity of the peptide sequence with a stretch of 14 AA within the protein sequence of VSG LiTat 1.3. % RA mAb-VSG: percentage remaining of the
mAb binding to its corresponding native VSG after inhibition by the synthetic peptide at 67 mg/ml.
doi:10.1371/journal.pntd.0001189.g002
Peptide Mimotopes of Trypanosoma brucei gambiense
www.plosntds.org 6 June 2011 | Volume 5 | Issue 6 | e1189protein epitopes are discontinuous and comprise critical binding
residues that are distant in the primary sequence but close in the
folded native tertiary protein structure. Indeed,WPLLT,the motive
of peptide 64 was mapped onto the three-dimensional VSG LiTat
1.3 protein structure, near the surface of the trypanosome. As
‘‘WPL’’ or ‘‘LPW’’ is part of the common motive in the peptide
sequences of group 2 (fig. 2) it is possible that the discontinuous
epitope of mAb H13F7 is localised in this region.
All 12-mer peptides that strongly inhibited the binding of the
mAbs to the VSG contain one or more proline residues. Proline
limits the flexibility of the peptide and may therefore favour the
forming of the mAb-peptide complex [30]. The 7-mer peptides are
already constrained by two flanking cysteines, which may account
for the fact that the sequence of four of the best cyclic inhibitors
contains no proline.
Cortese [31] reports that many mAbs fail to select specific
peptides. Due to the limitation of library complexity it is often
impossible to isolate peptides of high affinity and there is no
general rule applicable as to what type of library suits a certain
application [18]. In our study mAb H18C11 selected specific
peptides, but only with the 12-mer library. Additionally, all
phage clones selected with this mAb expressed the same peptide
sequence. It is possible that one phage clone overgrew other,
higher-affinity phage clones, during amplification. The peptide
selected with mAb H18C11 and some of the synthetic peptides
selected with mAb H12H3 and mAb H13F7 failed to react with
the corresponding mAb in indirect ELISA. It has been described
before that phage-born peptides can lose their ability to bind the
target molecule when synthesised chemically [17]. Furthermore
the conformation of peptides in binding assays may differ from
the presentation on the phage. Although direct coating was only
successful for some peptides (data not shown), we successfully
demonstrated the capacity of several of these peptides in
solution to inhibit the binding of their mAb to the correspond-
ing VSG. Based on these results we selected some peptides for
resynthesis and biotinylation. The biotinylated peptides were
bound to streptavidin, which was coated onto the ELISA plate,
this improved the peptide presentation to such an extent that all
of the biotinylated peptides were able to bind their correspond-
ing mAb.
Although the aim of our study was to identify mimotopes for
antibody detection in human serum, we opted to perform the
panning with mouse monoclonal antibodies. Indeed, sera from
sleeping sickness patients contain an important fraction of
trypanosome unrelated antibodies as a consequence of polyclonal
B cell stimulation [32,33]. Therefore, the risk to select mimotopes
unrelated to sleeping sickness by applying human sera for the
panning is considerable, unless only the trypanosome specific
antibody fraction of these sera is used. Moreover, it was
demonstrated that mAbs identified peptide mimotopes similar to
those selected with pooled sera of typhus patients [21]. Also, mAb
H13F7 was able to cause lysis of trypanosomes of VAT LiTat 1.3
in the immuno-trypanolysis test, which demonstrates that this
mAb recognises VSG epitopes, exposed on living bloodstream
trypanosomes, similar to those recognised by human sleeping
sickness sera [3]. Finally, we chose to perform the screening with
mAbs that bind to different epitopes on the VSGs to increase the
chance that the selected mimotopes would bind different
antibodies in the polyclonal patient sera.
Human sleeping sickness sera inhibited the binding of anti-
LiTat 1.5 mAb H12H3 to peptides 21, 22, 23, 28, C59 and C60
and the binding of anti-LiTat 1.3 mAb H13F7 to peptides 25, 60
and 61, auguring for their value as diagnostic antigens. Not all
peptides were equally well recognised by human sera. It is possible
that some peptides react weakly with positive sera in spite of their
specificity for immunodominant regions, which can be explained if
these peptides mimic only part of the structure of the
corresponding region on the antigen [20]. This may be the reason
why the mimotopes corresponding to the linear region in the
protein sequence of VSG LiTat 1.5 that interacts with the mAb
seem to be more easily recognised by human antibodies than the
mimotopes of the discontinuous LiTat 1.3 epitope, where a correct
conformational presentation is crucial. The mouse and human
immune system may as well react with different vigour to certain
epitopes or recognise different principal epitopes. The fraction of
antibodies in HAT sera that bind the same epitope as the mAbs
may therefore be relatively small. By using an inhibition ELISA,
low serum dilutions could be applied, maximising the reaction
with the peptides, but avoiding the non-specific reactions often
observed with HAT sera at low dilutions. Unexpectedly, with
Figure 3. Average percent remaining activity of the mAb binding to the biotinylated synthetic peptides. The ability of human serum
antibodies to bind to the mimotopic peptides selected with anti-VSG monoclonal antibodies was assessed by means of an inhibition ELISA. *: p,0.05
and **: p,0.01. Compared to the ten HAT negative sera, the nine HAT positive sera significantly inhibited the binding of anti-LiTat 1.5 mAb H12H3 to
peptide 21, 22, 23, 28, C59 and C60 and the binding of anti-LiTat 1.3 mAb H13F7 to peptides 25, 60 and 61.
doi:10.1371/journal.pntd.0001189.g003
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resulted in higher ODs than those obtained with the serum-free
control wells. This observation might be explained if human serum
contains a substance that changes the conformation of a peptide in
a way that facilitates binding to the mAb.
With this study, we aimed at delivering the proof of principle
that mimotopes for VSGs can be selected from a peptide phage
display library making use of mAbs. However, the study has some
limitations. Firstly, by making use of only three mAbs, it is likely
that other diagnostic mimotopes have been missed. Secondly, no
affinity measurements e.g. via surface plasmon resonance, have
been performed. Considering the polyclonal character of antibod-
ies in patients’ sera and the inherent differences in antibody
response between individual patients, we opted to assess only the
diagnostic potential of the selected peptides by means of ELISA.
In conclusion, we successfully demonstrated that polyclonal
antibodies in human sleeping sickness sera recognise mimotopes of
VSG LiTat 1.3 and 1.5, indicating diagnostic potential of peptides
selected with monoclonal antibodies. Still, replacement of the
native T.b. gambiense LiTat 1.3 and LiTat 1.5 VSGs in the currently
existing diagnostic formats might not be straightforward. It should
be preceded by confirming the diagnostic potential of the selected
peptides, or variations and combinations thereof, on larger panels
of HAT positive and negative sera, and, if needed, peptide
sequence optimisation.
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